Medication info

Seviterra Tablet 10/40 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
Brownish-red round film-coated tablets
Packaging
For domestic use - 30 tablets/box [(10 tablets/PTPX3)]
Approval status
Expired

MFDS item code 202002846 · Approved 2020.04.22

This product's status changed to Expired on 2025.04.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the medicine at the same time every day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients Who Should Not Receive This Medicine under Precautions for Use.) ∘Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored closely and more frequently.
Child dose
∘Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil. It helps to effectively lower blood pressure and reduce the risk of complications related to hypertension. Therefore, it is a suitable treatment for those who struggle with blood pressure management.

How to take

Adult dose

Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the medicine at the same time every day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients Who Should Not Receive This Medicine under Precautions for Use.) ∘Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored closely and more frequently.

Child dose

∘Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it must be discontinued immediately if pregnancy is confirmed. It is prudent not to take this medication if you have an allergy to any of its components or similar medication classes, are pregnant or breastfeeding, or have severe liver disease or certain heart conditions. Patients with a deficiency in body fluids or electrolytes should be carefully monitored, as blood pressure may drop excessively upon first use of this medication. It should be used cautiously in patients with severe heart conditions or those with rapidly dilating blood vessels, as symptoms may worsen after taking this medication. Patients with impaired kidney function or weak liver function should consult a healthcare provider before use, as this medication may affect the kidneys and liver. Various side effects may occur with this medication, including dizziness, headaches, low blood pressure, indigestion, and skin rashes. Particularly, potassium levels in the blood may increase, thus caution is advised when taken with medications that can raise potassium levels. During pregnancy, this medication can be dangerous to the fetus, so it is essential to consult a physician if you plan to become pregnant or are already pregnant. Breastfeeding women are advised to stop breastfeeding or discontinue this medication, as it can be passed into breast milk and may affect the infant. The safety and efficacy of this medication have not been firmly established in children under 18 years of age, and it is not recommended. Elderly patients should start with a low dose and take it cautiously as there may be declines in kidney and liver function. In the case of an overdose, severe blood pressure reduction and symptoms due to vasodilation may occur, requiring immediate medical attention. This medication should be stored in a tightly sealed container protected from light and moisture, and it is advisable not to transfer it to other containers.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory decline
  • syncope
Show 80 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • pollakiuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • weakness
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • diplopia
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • jaundice
  • increased liver enzymes
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a sealed container to protect it from air and moisture. It is also safe to store it at room temperature, avoiding extremely hot or cold conditions, preferably between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Brownish-red round film-coated tablets

Package unit

For domestic use - 30 tablets/box [(10 tablets/PTPX3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.